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Abstract
The goal of the Malaria Vaccine Program at the Walter Reed Army Institute of Research (WRAIR) is to develop a licensed multi-antigen,
multi-stage vaccine against Plasmodium falciparum able to prevent all symptomatic manifestations of malaria by preventing parasitemia. A
secondary goal is to limit disease in vaccinees that do develop malaria. Malaria prevention will be achieved by inducing humoral and cellular
immunity against the pre-erythrocytic circumsporozoite protein (CSP) and the liver stage antigen-1 (LSA-1). The strategy to limit disease
will target immune responses against one or more blood stage antigens, merozoite surface protein-1 (MSP-1) and apical merozoite antigen-1
(AMA-1). The induction of T- and B-cell memory to achieve a sustained vaccine response may additionally require immunization with an
adenovirus vector such as adenovirus serotype 35. RTS,S, a CSP-derived antigen developed by GlaxoSmithKline Biologicals in collaboration
with the Walter Reed Army Institute of Research over the past 17 years, is the cornerstone of our program. RTS,S formulated in AS02A
(a GSK proprietary formulation) is the only vaccine candidate shown in field trials to prevent malaria and, in one instance, to limit disease
severity. Our vaccine development plan requires proof of an individual antigen’s efficacy in a Phase 2 laboratory challenge or field trial prior
to its integration into an RTS,S-based, multi-antigen vaccine. Progress has been accelerated through extensive partnerships with industrial,
 Presented in part at the World Congress on Vaccines and Immunology, Tsukuba City, Japan, 5 October, 2004.
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academic, governmental, and non-governmental organizations. Recent safety, immunogenicity, and efficacy trials in the US and Africa are
presented, as well as plans for the development of a multi-antigen vaccine.
© 2005 Published by Elsevier Ltd.
1. Introduction
The Walter Reed Army Institute of Research (WRAIR)
in Silver Spring, Maryland is dedicated to developing drugs,
diagnostic devices, and vaccines to protect military personnel
against disease, particularly tropical diseases such as malaria
[1]. Military medical research has led to the development
and field-testing of anti-malarial drugs including mefloquine,
primaquine, doxycycline, atovaquone-proguanil (Malarone),
tafenoquine, and halofantrine that are active against drug-
resistant strains of Plasmodium falciparum [2]. These anti-
malarial drugs have demonstrated substantial public health
benefit. Despite the availability of modern antimalarial drugs,
mosquito-repellants, bed nets and other countermeasures,
malaria threatens the success of modern militaries, most
recently Australian and Thai forces in East Timor (2000),
British troops in Sierra Leone (2001) and the US Marines
in Liberia (2003). The US military requires a safe, well-
tolerated highly effective vaccine that prevents malaria or
very significantly limits the severity of disease in vaccinees
who develop malaria, and confers sustained protection. En-
demic populations suffer some 3 million deaths and 500 mil-
lion episodes of this dread disease annually [3]. A vaccine
with this profile may also be of potential public health ben-
efit to these populations. Recent excellent reviews broadly
address the status of current malaria vaccine efforts, consid-
erations in vaccine design, and the formidable obstacles to
vaccine development [4–6]. This brief article focuses on the
successful WRAIR-GSK partnership that led to the RTS,S-
based malaria vaccine candidates, the results and implications
of recent RTS,S/AS02A clinical and field trials, and then out-
lines plans to develop an RTS,S-based multi-antigen, multi-
stage malaria vaccine that would fulfill the requirements of
the US military.
2. Development of RTS,S
2.1. Initial circumsporozoite protein vaccines
The gene coding for the circumsporozoite protein (CSP)
was the first P. falciparum gene to be identified and
cloned [7]. The CS proteins of all malaria species con-
tain a central segment of species-specific amino acid re-
peat sequences flanked by non-repeat regions [8,9]. In
the case of P. falciparum, the central portion contains
approximately 40 repeats of the amino acid sequence
asparagin–alanine–asparagines–proline (NANP) and several
asparagines–valine–aspartic acid–proline (NVDP) repeats
[10]. The central repeating region contains immunodomi-
nant B-cell epitope(s) [11], whereas the majority of epitopes
responsible for the induction of CD4 and CD8 T-cells are
located within the flanking regions. Two alum-adjuvanted
candidate vaccines based on the CSP repeat sequences were
developed in the mid 1980s [12], tested in humans at the Uni-
versity of Maryland [13] and at WRAIR [14], and found to
be safe; however, both suffered from generally poor immuno-
genicity. In most volunteers, repeated immunization induced
relatively low titers of antibodies against the repeat region of
the CSP. Nevertheless, a small number of volunteers who did
respond well were protected against homologous experimen-
tal sporozoite challenge. These encouraging challenge data
served as a proof of concept that antibody-mediated sterile
immunity against malaria could be induced in humans by im-
munization with a recombinant or synthetic pre-erythrocytic
stage subunit vaccine. In these studies with a limited number
of volunteers, protection seemed to be associated with high
antibody levels; therefore, it was assumed that the develop-
ment of more immunogenic versions of these vaccines would
lead to better efficacy. Subsequent sporozoite vaccines, also
based on the NANP repeats, contained modifications con-
ducive to the enhancement of humoral immune responses,
such as conjugation of recombinant CSP repeat region with
Pseudomonas aeruginosa exotoxin A (R32ToxA)[15] and
formulation of a similar antigen (R32NS1) in liposomes
containing monophosphoryl lipid A (MPL)[16] or an emul-
sion of MPL, mycobacterial cell wall skeleton, and squa-
lene (Detox®, Ribi Immunochem) [17,18]. Each of these
strategies resulted in generally higher antibody levels, but
surprisingly did not significantly enhance efficacy upon live
sporozoite challenge [19–21], thus suggesting that antibody
responses to NANP repeats were not alone sufficient to in-
duce significant protective efficacy.
2.2. WRAIR-GSK development of RTS,S
While these clinical studies were in progress, the role
of protective T-cell responses directed against the liver-
stage form of the parasite was elucidated in greater de-
tail. Studies in rodents and humans immunized with irra-
diated sporozoites revealed that not only antibodies, but also
CD4 and CD8 cells that exhibited cytotoxic T-cell (CTL)
responses or produced cytokines such as interferon- were
important components of the protective immune network
against the pre-erythrocytic stage of P. falciparum [22]. Tar-
get epitopes for these T-cells have been localized to the C-
terminal region of the CSP [23–26]. The recognition that
peptide sequences lying outside the CSP repeat were im-
portant for induction of humoral and cellular responses
against the hepatic stage led to the inclusion of non-repeat
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portions of the molecule in the next generation of CSP-based
vaccines.
In 1984, GlaxoSmithKline in collaboration with WRAIR
pioneered the use of the hepatitis B surface antigen (HB-
sAg) as a carrier matrix for the central repeat region of the
P. falciparum CSP [27]. The initial construct, referred to
as R16-HBsAg, was formulated with alum; it proved safe
and immunogenic in 20 hepatitis B-seronegative adults at the
University of Nijmegen [28]. In 1987, following the recog-
nition of the potential role of cell-mediated immunity and
of non-repeat sequence of CSP, a new CSP–HBsAg fusion
protein was developed at GSK, which incorporated the CSP
C-terminal flanking region known to contain B- and T-cell
epitopes into a chimeric gene expressed in Saccharomyces
cerevisiae. This construct was named “RTS” to indicate the
presence of the CSP repeat region (R), T-cell epitopes (T), and
the hepatitis B surface antigen (S). Exigencies of purification
led to the co-expression and purification of additional anti-
gen in a ratio of RTS to S of 1:4, hence the name “RTS,S.” A
process compatible with GMP manufacturing of RTS,S was
then developed at GSK.
2.3. First trials of RTS,S
The first clinical trial of RTS,S evaluated two formulations
developed at GSK for safety and efficacy in malaria naı¨ve
adults in 1992 at the Walter Reed Army Institute of Research,
The formulations were RTS,S and alum (N= 10), and RTS,S
with monophosphoryl lipid A and alum (N= 10). Both vac-
cines proved to be safe and well tolerated. RTS,S/MPL/alum
elicited higher antibody responses against the CSP repeat
and C-terminal region than did RTS,S/alum. After sporo-
zoite challenge, zero of six RTS,S/alum vaccinees and two
of eight RTS,S/MPL/alum vaccinees were protected [29].
These encouraging results were considered to warrant fur-
ther improvement of the vaccine. Consequently, GSK and
WRAIR initiated a rigorous comparative preclinical safety
and immunogenicity evaluation of six GSK proprietary for-
mulations of RTS,S in rhesus monkeys at the Armed Forces
Research Institute of Medical Sciences to improve upon
both the humoral and cell-mediated immunogenicity of
RTS,S/MPL/alum. One formulation, consisting of RTS,S for-
mulated in an oil-in-water emulsion with MPL and QS21,
demonstrated superior antibody and delayed type hypersen-
sitivity responses, and is today designated RTS,S/AS02A
[30].
2.4. First trials of RTS,S/AS02
In 1996, volunteers immunized with either RTS,S/AS03
(an oil-in-water emulsion without additional adjuvants) or
RTS,S/AS02A in a Phase 2A trial at WRAIR developed
the highest anti-repeat antibody responses ever induced by
a CS-based vaccine, but RTS,S/AS02A induced a higher
T-cell response as measured by IFN- production in an
ELISPOT assay [31]. Following laboratory-based sporo-
zoite challenge, the RTS,S/AS03 formulation was marginally
protective (two of seven); in contrast, RTS,S/AS02A pro-
tected an unprecedented six of seven volunteers [32]. A sin-
gle determination of the duration of protection 6 months
after initial challenge found that only one of five previ-
ously protected RTS,S/AS02A-immunized volunteers was
still protected [33]. Preliminary dose optimization stud-
ies at WRAIR have since confirmed that two or three
doses of RTS,S/AS02A consistently confer significant pro-
tection (sterile immunity) and significant delays in the
prepatent period in RTS,S/AS02A vaccinees who develop
malaria as compared to concurrent infectivity controls
[34].
2.5. Lyophilized RTS,S
After stability testing revealed a limited shelf life of RTS,S
in the AS02A adjuvant, RTS,S was reformulated at GSK as
a stable frozen lyophilized cake and filled in single dose
vials for reconstitution with AS02A just prior to injection.
A comparative trial at WRAIR demonstrated the equiva-
lent safety and immunogenicity of the liquid and lyophilized
preparations. Further, lyophilized RTS,S formulated with
AS02A provided equivalent protection against experimental
malaria challenge as well as the earlier liquid RTS,S/AS02A
formulation (Kester, unpublished results). Subsequent tri-
als of RTS,S have all been performed with the lyophilized
version.
2.6. Accelerated RTS,S/AS02A schedules
During initial trials, the RTS,S/AS02A vaccine was ad-
ministered on a 0-, 1- and 6–9-months schedule. Subse-
quently, a Phase 2A trial at WRAIR compared the safety,
immunogenicity and efficacy of lyophilized RTS,S, formu-
lated with AS02A on two different accelerated schedules.
Forty volunteers received a full dose of RTS,S/AS02A on ei-
ther a 0-, 1- and 3-months schedule (N= 20) or on a 0-, 7-,
and 28-days schedule (N= 20). Following standard sporo-
zoite challenge, 45 and 38%, respectively, of vaccinees were
completely protected against malaria and there was no in-
crease in reactogenicity versus historical controls (Kester,
unpublished results). These data provided support for subse-
quent accelerated schedules of evaluation for RTS,S/AS02A
in Africa and for other candidate antigens adjuvanted with
AS02A at WRAIR.
2.7. RTS,S/AS02A field trials
The initial trial of RTS,S/AS02A, conducted by the Medi-
cal Research Council (MRC) in The Gambia in healthy adult
males, demonstrated unprecedented effects, namely a 34%
reduction in instance of first parasitemia (95% CI 8–53%;
p= 0.014) over a 16-weeks efficacy period [35,36], and effi-
cacy appeared not to be strain specific [37]. Subsequently,
GSK and the Malaria Vaccine Initiative at PATH (MVI)
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entered into a partnership that has sponsored the initiation
of pediatric clinical development of RTS,S/AS02A. In ini-
tial pediatric studies conducted by the MRC in The Gambia
and CISM in Mozambique, the vaccine was shown to be safe
and highly immunogenic in children 1–11 years of age (Bo-
jang et al., submitted for publication; Macete et al., submitted
for publication). In the recently reported Phase 2B efficacy
study conducted by CISM and the University of Barcelona
in Mozambique, it was reported that over a 6-months pe-
riod in children 1–4 years of age, RTS,S/AS02A conferred
30% (95% CI 12–45%; p= 0.004) efficacy for first clinical
episodes and 58% (95% CI 16–81%; p= 0.019) efficacy for
severe malaria due toP. falciparum [38]. Longitudinal follow-
up is in progress to define the long-term safety and the mag-
nitude and duration of RTS,S/AS02A’s benefit in young chil-
dren, and studies are planned to develop an RTS,S vaccine
for infants in conjunction with the Expanded Program on
Immunisation [39].
3. Potential RTS,S improvements
Until the correlates of vaccine-induced protective immu-
nity are known, Phase 2A challenge and Phase 2B field
trials will be required to confirm the efficacy of particular
improvement strategies. Decision points for integrating im-
provements are listed in Table 1.
3.1. RTS,S efficacy
Efficacy estimates for Phase 2A trials of RTS,S/AS02A
based only on the occurrence of parasitemia overlook the
important biologic effect represented by the consistent pro-
longation of the prepatent period in RTS,S/AS02A vacci-
nees. In recent trials, approximately 40% of adult volunteers
immunized with two or three doses of RTS,S/AS02A expe-
rience complete protection and an additional 40–45% note
a roughly 2 days delay in the pre-patent period when com-
pared to simultaneous infectivity controls. This effect is at-
tributable to either a reduction of viable sporozoites or to
an interruption of hepatic schizogony or both resulting in
a significant reduction in the release of hepatic merozoites
[34,40]. Encouraged by these results, we have embarked
on parallel development efforts to augment RTS,S/AS02A
efficacy.
3.2. RTS,S and an adenovirus vector
In 1997, scientists at New York University’s (NYU)
School of Medicine first reported in a series of publications
that a recombinant adenovirus expressing the CSP generated
sustained protection in mice against lethal challenge with
P. yoelii sporozoites by a variety of immune mechanisms
[41–43]. Later, in a joint effort between NYU and Crucell,
a biotechnology company in the Netherlands, it was shown
that a novel recombinant adenovirus 35 vector expressing
CSP also protected mice against P. yoelli (Goudsmit, unpub-
lished). The recombinant adenovirus 35 is a non-replicating
viral vector chosen for clinical vaccine development be-
cause there is minimal worldwide seroprevalence of neutral-
izing antibody that would interfere with its use as a vaccine
[44–47]. Recently, a collaboration between Crucell, GSK,
and WRAIR was established for the purpose of testing an
adenovirus 35 (Ad 35) CSP vaccine directed against P. fal-
ciparum, designated Ad 35 CS as well as the combination
of Ad 35 CS and RTS,S in a so called “prime/boost” regi-
men. Thus, in 2003 preclinical evaluations began of Ad 35
CS alone and in combination with RTS,S in the standard rhe-
sus monkey safety and immunogenicity model at WRAIR.
Contingent upon the results of this study, Phase 2A clinical
trials are planned for 2006, with the support of the National
Institute of Allergy and Infectious Diseases.
3.3. RTS,S with additional antigens
We expect that the efficacy of an RTS,S-based malaria
vaccine could be improved by combination with one or more
protective antigens. Our vaccine development strategy is first
to establish a protective effect of additional protein antigens
prior to co-formulating them with RTS,S as a combined,
multi-antigen vaccine.
3.3.1. Merozoite surface protein-1 (MSP-1)
Merozoite surface protein-1, the first antigen discovered
on the surface of erythrocytic stage merozoites, is also ex-
pressed in all generations of merozoites, including those re-
leased at the end of hepatic schizogony [48]. The C-terminal
portion of the MSP-1 is the target of protective immunity as
suggested by epidemiological studies [49,50] and as demon-
strated by the protection of Aotus monkeys against malaria
challenge by immunization with 42-kDa C-terminal MSP-1
Table 1
Scheduled evaluation of potential RTS,S improvements
Technology Rationale Example Criteria and location Decision date
Antigen Target hepatic stage parasites Liver stage antigen-1 (LSA-1) Phase 2A at WRAIR 2006
Antigen Target blood stage Merozoite surface protein-1 (MSP-1) Phase 2B in Kenya 2006
Antigen Target blood stage Apical merozoite antigen-1 (AMA-1) Phase 2B in Mali 2007
Vector Increase magnitude and duration of CMI Adeno 35/full length CSP (Ad 35 CS) Phase 2A at WRAIR 2007
CMI: cell-mediated immunity; Phase 2A: preliminary vaccine efficacy trial against experimental malaria challenge; Phase 2B: preliminary vaccine efficacy
trial in malaria endemic country; CSP: circumsporozoite protein; and Adeno 35: adenovirus serotype 35.
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recombinant protein [51,52]. In the late 1990s, with sus-
tained support from the USAID and in the context of the
GSK/WRAIR collaborations, a 42-kDa C-terminal MSP-1
protein based on the P. falciparum 3D7 clone was manu-
factured to GMP standards at the WRAIR [53]. In preclin-
ical [54] and Phase 1 trials at WRAIR, MSP-1 formulated
with AS02A proved to be safe and highly immunogenic,
eliciting high titer antibodies as measured by ELISA and
by immunofluorescence assay against parasitized red blood
cells, as well as T-cell responses characterized by IFN-
production. The volunteers also produced functional anti-
body as measured by an in vitro growth inhibition assay
(Ockenhouse, unpublished). A subsequent Phase 2A trial
at WRAIR tested MSP-1/AS02A alone and in combination
with RTS,S/AS02A. MSP-1/AS02A alone did not delay par-
asitemia, and in combination with RTS,S/AS02A it did not
improve upon or interfere with the protective efficacy of
RTS,S/AS02A. The trial design required treating volunteers
as soon as they developed a detectable parasitemia, and thus
the data did not allow determination as to whether or not
MSP-1/AS02A would limit parasitemia and disease (Cum-
mings, unpublished). Next, the MVI, USAID, GSK, WRAIR
and the Kenya Medical Research Institute (KEMRI) con-
ducted Phase 1 trials of the MSP-1/AS02A in adults and
in children in malaria endemic Western Kenya from 2002
to 2004. In parallel, and with the additional support of the
NIAID, University of Bamako investigators completed an
additional Phase 1 safety and immunogenicity trial of MSP-
1/AS02A in healthy adults in Bandiagara, Mali in 2004. On
the basis of the favorable safety and immunogenicity data
for MSP-1/AS02A, an independent Data Safety Monitoring
Board recommended proceeding to a Phase 2B trial in chil-
dren ages 1–4 years. This trial will commence in 2005, with
support from MVI, USAID, and GSK, and will evaluate vac-
cine efficacy against clinical disease in children in Western
Kenya.
3.3.2. Apical merozoite antigen-1 (AMA-1)
Apical merozoite antigen-1 (AMA-1), originally identi-
fied as a blood stage protein, is an essential antigen [55]
expressed in sporozoite [56], late stage hepatic parasites
[57], and in erythrocytic merozoites. AMA-1, like MSP-1,
is the target of protective immunity, as supported by epi-
demiological observations [58], in vitro demonstrations [55],
and by protection studies in which mice [59] or monkeys
[60] immunized with recombinant forms of AMA-1 were
protected from lethal challenge with homologous parasites.
Scientists at the WRAIR have produced a correctly folded
GMP recombinant protein in E. coli based upon the P. fal-
ciparum 3D7 strain AMA-1 ectodomain [61]. This antigen
was vialed as a single-dose lyophilized cake intended for
formulation with AS02A just prior to administration. In the
context of the GSK/WRAIR collaboration, a Phase 1A dose-
escalating trial was conducted at WRAIR’s Clinical Trials
Center in 2003. Twenty-three healthy adult volunteers re-
ceived three intramuscular doses of AMA-1 formulated with
AS02A adjuvant on a 0-, 1-, and 2-months schedule. AMA-
1/AS02A proved safe and immunogenic. Volunteers devel-
oped parasite-specific antibody by IFA, functional antibody
as measured by an in vitro growth inhibition assay, and cellu-
lar responses as measured by lymphoproliferative and IFN-
responses by ELISPOT assays (Polhemus, unpublished). Two
additional trials of AMA-1/AS02A are underway. A Phase
1B controlled trial in Bandiagara, Mali, supported by the Na-
tional Institute of Allergy and Infectious Diseases and led by
investigators from the University of Bamako, is underway to
evaluate two different doses of AMA-1/AS02A in healthy
adults on a 0-, 1-, and 2-months schedule. A Phase 2B trial
of AMA-1/AS02A in children at risk of disease with the pri-
mary endpoint of clinical disease is planned for 2006 in West
Africa.
3.3.3. Liver stage antigen-1 (LSA-1)
Liver stage antigen-1 was identified as a potential vaccine
antigen in 1990 [62]. There are no accepted homologues
of this P. falciparum antigen in murine or simian plas-
modia. Therefore, the case for LSA-1 as a vaccine candidate
rests upon strong epidemiological correlations of immune re-
sponses with clinical immunity to malaria in malaria-endemic
populations, and with the correlation of acquired LSA-1 im-
mune responses with protection in irradiated sporozoite im-
munization studies [63]. WRAIR scientists have produced E.
coli-expressed recombinant P. falciparum LSA-1 protein un-
der GMP conditions as a candidate malaria vaccine. In 2004,
WRAIR partnered with GSK and PATH’s Malaria Vaccine
Initiative to develop LSA-1 as a vaccine [64]. Phase 2A trials
are planned for late 2005/early 2006 at WRAIR’s Clinical
Trials Center that will evaluate the safety, immunogenicity
and efficacy of LSA-1.
4. Conclusion
RTS,S/AS02A, the candidate malaria vaccine in the most
advanced stage of development, is the result of a sustained
17-years effort by partners committed to the development
of a malaria vaccine. The immunologic correlates of RTS,S-
induced protection have not been identified yet but trends
have begun to emerge, allowing more rational development
to supplant empiricism, and to enable a greater focus of re-
sources on the most promising potential improvements of
RTS,S. The recent report that RTS,S/AS02A had a significant
positive impact on clinical and severe malaria in children in
Mozambique strongly support our working hypothesis that a
more effective RTS,S-based vaccine could be developed that
would better meet the US Army military needs and perhaps
also benefit global public health needs.
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